incomplete freund's adjuvant
Biologicalexperimental
Clinical trial activity
59 trials · 24 clinical orgs · 0 marketing orgs
Phase 1
20
Phase 2
39
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 1996 (NCT00003224)
Timeline
Indications
Studied for
- Acne Vulgaris · Phase 1
- Bile Duct Neoplasms · Phase 2
- Breast Neoplasms · Phase 1
- Carcinoma, Renal Cell · Phase 2
- Colorectal Neoplasms · Phase 2
- Conjunctival Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 1
- Gallbladder Neoplasms · Phase 2
- Hamartoma · Phase 1
- Intestinal Neoplasms · Phase 2
- Leukemia · Phase 1
- Lung Neoplasms · Phase 2
- Melanoma · Phase 2
- Mesothelioma, Malignant · Phase 1
- Multiple Myeloma · Phase 1
- Multiple Sclerosis · Phase 2/Phase 3
- Myelodysplastic Syndromes · Phase 2
- Neoplasms · Phase 2
- Neuroendocrine Tumors · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Stomach Neoplasms · Phase 2
Mechanism of action
- UnclearImmunity, active
Unclear immunity, active
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650400 ↗
Also known as
- incomplete freund's adjuvant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06202066 | Phase 2 | Dec 15, 2024 | State University of New York, Buffalo |
| NCT03879694 | Phase 1 | Jun 13, 2019 | NeuroEndocrine Tumor Research Foundation (NETRF), State University of New York, Buffalo |
| NCT02200718 | Phase 1 | Nov 1, 2017 | Oregon Health and Science University, The Immune Response Corporation |
| NCT02149706 | Phase 2 | Mar 1, 2017 | Oregon Health and Science University, The Immune Response Corporation |
| NCT02057159 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2017 | Oregon Health and Science University, The Immune Response Corporation |
| NCT02334865 | Phase 1 | Mar 9, 2016 | Celgene, National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT02126579 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2014 | University of Virginia |
| NCT01673217 | Phase 1 | Apr 1, 2009 | Eisai, National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT00640861 | N/A | Aug 1, 2008 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00706992 | Phase 2 | Jun 1, 2008 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00705640 | Phase 1 | May 1, 2008 | National Cancer Institute (NCI), University of Virginia |
| NCT00513578 | Phase 2 | Jan 1, 2007 | The Vaccine Company |
| NCT00398138 | Phase 1 | Oct 1, 2006 | Cornell University, Innovive Pharmaceuticals, National Cancer Institute (NCI) |
| NCT00381875 | Phase 1 | Jul 1, 2006 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00357461 | Phase 2 | May 1, 2006 | Bristol-Myers Squibb, National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00295958 | Phase 2 | Dec 1, 2005 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00303836 | Phase 2 | Nov 1, 2005 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00109811 | Phase 2 | Mar 1, 2005 | National Cancer Institute (NCI), University of Maryland |
| NCT00118274 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2005 | National Cancer Institute (NCI), University of Virginia |
| NCT00071981 | Phase 2 | Mar 1, 2005 | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), University of Virginia |
Showing 20 of 59 trials
Page 1 / 3
Organizations
Research & Development (24)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 51 | 18 | 3 | 1996 |
| National Institutes of Health (NIH) | Government | 20 | 5 | 2 | 1998 |
| University of Virginia | Academic/Hospital | 10 | 9 | 2 | 1996 |
| University of Southern California | Academic/Hospital | 7 | 6 | 2 | 1998 |
| State University of New York, Buffalo | Academic/Hospital | 4 | 4 | 2 | 2009 |
| Cornell University | Academic/Hospital | 3 | 3 | 2 | 1998 |
| Oregon Health and Science University | Academic/Hospital | 3 | 0 | 3 | 2017 |
| The Immune Response Corporation | For profit | 3 | 3 | 3 | 2017 |
| Eastern Cooperative Oncology Group | Academic/Hospital | 2 | 2 | 1 | 2000 |
| Mayo Clinic | Academic/Hospital | 2 | 1 | 1 | 2000 |
| University of Maryland | Academic/Hospital | 2 | 1 | 1 | 2000 |
| Bristol-Myers Squibb | For profit | 1 | 1 | 1 | 2006 |
| Celgene | For profit | 1 | 0 | 1 | 2016 |
| Eisai | For profit | 1 | 0 | 1 | 2009 |
| Epimmune | For profit | 1 | 1 | 1 | 2004 |
| Innovive Pharmaceuticals | For profit | 1 | 0 | 1 | 2006 |
| NeuroEndocrine Tumor Research Foundation (NETRF) | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Providence Health & Services | Academic/Hospital | 1 | 1 | 1 | 2004 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 2002 |
| The Vaccine Company | For profit | 1 | 1 | 1 | 2007 |
24 organizations
Page 1 / 2